Palisade Bio's shares surge 37% on strategic collaboration with Strand Life Sciences for precision medicine in ulcerative colitis therapy.

Palisade Bio's (NASDAQ: PALI) shares jumped 37% after announcing a strategic collaboration with bioinformatics firm Strand Life Sciences to advance precision medicine for ulcerative colitis therapy. Access to Strand's advanced tools will aid in understanding complex disease pathways and predicting responses to PDE4 inhibitors. Wall Street currently holds a consensus "buy" rating on Palisade Bio stock.